Amerikanische Gesellschaft für Hirudotherapie

Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management

Review published in Chest (2009)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungKlinische StudienShantsila E et al. · Chest, 2009

Abstract

Thrombocytopenia following heparin administration can be associated with an immune reaction, now referred to as heparin-induced thrombocytopenia (HIT). HIT is essentially a prothrombotic disorder mediated by an IgG antiplatelet factor 4/heparin antibody, which induces platelet, endothelial cell, monocyte, and other cellular activation, leading to thrombin generation and thrombotic complications. Indeed, HIT can also be regarded as a serious adverse drug effect. Importantly, HIT can be a life-threatening and limb-threatening condition frequently associated with characteristically severe and extensive thromboembolism (both venous and arterial) rather than with bleeding. This article provides an overview of HIT, with an emphasis on the clinical diagnosis and management.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsArginineChondroitin SulfatesDermatan SulfateFemaleHeparinHeparan SulfateHirudinsHumansMaleMonitoring, PhysiologicPeptide Fragments

Zusammenfassung

Contemporary clinical review of HIT pathophysiology (anti-PF4/heparin IgG, platelet activation, thrombin generation) and management algorithms incorporating direct thrombin inhibitors lepirudin and argatroban.

Warum dies für die Hirudotherapie relevant ist

This review provides an overview of heparin-induced thrombocytopenia (HIT), a prothrombotic immune-mediated adverse drug reaction mediated by IgG antiplatelet factor 4/heparin antibodies, with emphasis on clinical diagnosis and management. The abstract describes HIT's pathogenesis, association with severe venous and arterial thromboembolism, and its character as a life- and limb-threatening condition. The article has no direct relevance to ASH's domain: the abstract does not mention hirudin, lepirudin, leeches, leech-derived therapy, or the leech secretome, and contains no discussion of hirudotherapy. CAVEAT: This is a review article offering a clinical overview; the abstract provides no content on leech-derived agents or related therapies, making its relevance to ASH's core domain negligible.

Zitation

Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.

Shantsila E et al. · Chest, 2009

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsClinical EvidenceClinical ApplicationsHirudinAnticoagulation CompoundsHemostasisOtolaryngologyPulmonology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.